Exosomal miR-1290 is a potential biomarker of high-grade serous ovarian carcinoma and can discriminate patients from those with malignancies of other histological types

被引：0

作者：

Masaki Kobayashi

Kenjiro Sawada

Koji Nakamura

Akihiko Yoshimura

Mayuko Miyamoto

Aasa Shimizu

Kyoso Ishida

Erika Nakatsuka

Michiko Kodama

Kae Hashimoto

Seiji Mabuchi

Tadashi Kimura

机构：

[1] Osaka University Graduate School of Medicine,Departments of Obstetrics and Gynecology

[2] H. Lee Moffitt Cancer Center & Research Institute,Department of Molecular Oncology

来源：

Journal of Ovarian Research | / 11卷

关键词：

microRNA; miR-1290; Ovarian cancer; HGSOC; Biomarker;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 34 条

[21] CIRCULATING MIRNA LANDSCAPE IDENTIFIES MIR-1246 AS PROMISING DIAGNOSTIC BIOMARKER IN HIGH-GRADE SEROUS OVARIAN CARCINOMA: A VALIDATION ACROSS TWO INDEPENDENT COHORTS
Bignotti, E.
Todeschini, P.
Salviato, E.
Paracchini, L.
Ferracin, M.
Petrillo, M.
Zanotti, L.
Tognon, G.
Gambino, A.
Calura, E.
Beltrame, L.
Odicino, F.
Sartori, E.
Scambia, G.
Negrini, M.
Ravaggi, A.
D'Incalci, M.
Marchini, S.
Romualdi, C.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 1439 - 1439
[22] IDENTIFICATION OF THE POPULATION OF PATIENTS WITH HIGH-GRADE SEROUS OVARIAN CARCINOMA WHO BENEFIT FROM OLAPARIB IN A MEDIUM-SIZED HOSPITAL
Kumagai, K.
Sakai, M.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 : 743 - 743
[23] Comprehensive mutation profiling by next-generation sequencing of effusion fluids from patients with high-grade serous ovarian carcinoma
Shah, Ronak H.
Scott, Sasinya N.
Brannon, A. Rose
Levine, Douglas A.
Lin, Oscar
Berger, Michael F.
CANCER CYTOPATHOLOGY, 2015, 123 (05) : 289 - 297
[24] CaMKK2-can: A dance between CaMKK2 and Rb in high-grade serous ovarian cancer patients with therapeutic potential
Previs, R. A.
Mukherjee, D.
Chang, C. Y.
Whitaker, R. S.
Strickland, K. C.
Berchuck, A.
Mcdonnell, D.
GYNECOLOGIC ONCOLOGY, 2019, 154 : 54 - 54
[25] Stratification of ovarian cancer borderline from high-grade serous carcinoma patients by quantitative serum NMR spectroscopy of metabolites, lipoproteins, and inflammatory markers
Bae, Gyuntae
Berezhnoy, Georgy
Koch, Andre
Cannet, Claire
Schaefer, Hartmut
Kommoss, Stefan
Brucker, Sara
Beziere, Nicolas
Trautwein, Christoph
FRONTIERS IN MOLECULAR BIOSCIENCES, 2023, 10
[26] Proteomic landscaping of high-grade serous ovarian carcinoma identifies stearoyl-CoA desaturase 5 as a potential predictive biomarker for poly(ADP-ribose) polymerase inhibitor response
Kim, Se Ik
Kim, Hyeyoon
Dan, Kisoon
Park, Hong-Beom
Lee, Cheol
Kim, Hee Seung
Chung, Hyun Hoon
Kim, Jae-Weon
Park, Noh Hyun
Han, Dohyun
Lee, Maria
CLINICAL AND TRANSLATIONAL MEDICINE, 2024, 14 (05):
[27] Extracellular Vesicle Characteristics in Local Fluid and Plasma Measured by Nanoparticle Tracking Analysis Can Help Differentiate High-Grade Serous Carcinoma from Benign Ovarian Pathology
Herzog, Marusa
Verdenik, Ivan
Cerne, Katarina
Kobal, Borut
DIAGNOSTICS, 2024, 14 (19)
[28] Potential risk factors associated with prognosis of neoadjuvant chemotherapy followed by interval debulking surgery in stage IIIc-IV high-grade serous ovarian carcinoma patients
Zhang, Jie
Liu, Ning
Zhang, Aihong
Bao, Xiangxiang
JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2018, 44 (09) : 1808 - 1816
[29] Prospective study of the efficacy and utility of TP53 mutations in circulating tumor DNA as a non-invasive biomarker of treatment response monitoring in patients with high-grade serous ovarian carcinoma
Kim, Yong-Man
Lee, Shin-Wha
Lee, Young-Jae
Lee, Ha-Young
Lee, Jong-Eun
Choi, Eun-Kyung
JOURNAL OF GYNECOLOGIC ONCOLOGY, 2019, 30 (03)
[30] Prospective study of the efficacy and utility of TP53 mutations in circulating tumor DNA as a non-invasive biomarker of treatment response monitoring in patients with high-grade serous ovarian carcinoma
Lee, Y. J.
Kim, Y. M.
Lee, S. W.
GYNECOLOGIC ONCOLOGY, 2019, 154 : 270 - 270

← 1 2 3 4 →